Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV
Sign Up to like & getrecommendations! Published in 2023 at "AIDS"
DOI: 10.1097/qad.0000000000003513
Abstract: Objective: To evaluate the safety and efficacy of switching highly treatment-experienced people with HIV (HTE PWH) from rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) plus dolutegravir (DTG) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus doravirine (DOR). A pharmacokinetic (PK) analysis was… read more here.
Keywords: taf plus; emtricitabine tenofovir; ftc taf; treatment ... See more keywords